Prolonged adenovirus-mediated expression of p27kip1 unveils unexpected effects of this protein on the phenotype of SUDHL-1 cells derived from t(2;5)-anaplastic large cell lymphoma

Leukemia Research

Volumn 27, Issue 4, 2003, Pages 329-335

  Turturro, Francesco ^a,b   Seth, Prem ^a  

^a DES MOINES UNIVERSITY   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Adenovirus; Apoptosis; Cell cycle; Integrins; Lymphoma; p27

Indexed keywords

ALPHA5 INTEGRIN; BETA5 INTEGRIN; INTEGRIN; PROTEIN P27; UNCLASSIFIED DRUG;

ADENOVIRUS; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CLONE; CELL CYCLE; CELL PROLIFERATION; CELL SURFACE; CELL SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LARGE CELL LYMPHOMA; MORPHOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR CELL; VIRUS INFECTION; VIRUS RECOMBINANT;

ADENOVIRIDAE; APOPTOSIS; CELL CYCLE PROTEINS; CHROMOSOMES, HUMAN, PAIR 2; CHROMOSOMES, HUMAN, PAIR 5; CLONE CELLS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; DOWN-REGULATION; ENZYME INHIBITORS; HUMANS; INTEGRINS; INTERPHASE; LYMPHOMA, LARGE-CELL, KI-1; PHENOTYPE; RECEPTORS, VITRONECTIN; TIME FACTORS; TRANSDUCTION, GENETIC; TRANSLOCATION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0037376997     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00167-4     Document Type: Article

References (16)

1. Kip1. Oncogene. 20:2001;4466-4475.
2. sdi1 gene transfer. Clin. Cancer Res. 5:1999;4233-4241.
3. Kip1 a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am. J. Pathol. 154:1999;313-323.
4. Sherr C.J. The Pezcoller Lecture: cancer cell cycles revisited. Cancer Res. 60:2000;3689-3695.
5. 5 integrin in SUDHL-1 cells derived from anaplastic large-cell lymphoma. Clin. Cancer Res. 6:2000;185-192.
6. Morgan R., Smith S.D., Hecht B.K., Christy V., Mellentin J.D., Warnke R.et al. Lack of involvement of the c-fms and N-myc genes by chromosomal translocation t(2;5)(p23;q35) common to malignancies with features of so called malignant hystiocytosis. Blood. 73:1989;2155-2164.
7. Kip1 induced cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene. 14:1997;2283-2289.
8. Kip1 on cell cycle and apoptosis in SUDHL-1 cells derived from anaplastic large lymphoma. Leukemia. 15:2001;1225-1231.
9. Kip1. J. Clin. Invest. 97:1996;1983-1988.
10. KIP1 to the confluence-dependent resistance of HT29 human colon carcinoma cells. Int. J. Cancer. 77:1998;796-802.
11. Kip1. J. Clin. Invest. 103:1999;597-604.
12. Varner J.A., Cheresh D.A. Integrins and cancer. Curr. Opin. Cell Biol. 8:1996;724-730.
13. Benharroch D., Meguerian-Bedoyan Z., Lamant L., Amin C., Brugieres L., Terrier-Lacombe M.J.et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood. 91:1998;2076-2084.
14. ν integrins. Science. 270:1995;1500-1502.
15. Turturro F., Heineke H.L., Drevyanko T.F., Link C.J., Seth P. Adenovirus-p53-mediated gene therapy of anaplastic large cell lymphoma with t(2;5) in a nude mouse model. Gene Ther. 7:2000;930-933.
16. Slingerland J., Pagano M. Regulation of the Cdk inhibitor p27 and its deregulation in cancer. J. Cell Physiol. 183:2000;10-17.